|
|
|
|
Muscular Dystrophy: Misplaced Enzyme Is to Blame for Quick Fatigue After Mild Exercise
Howard Hughes Medical Institute scientists have uncovered a molecular explanation for the profound fatigue brought on by mild exercise in some people with muscular dystrophy.The drugs might be helpful because they would increase...
|
|
|
Muscular Dystrophy: Misplaced Enzyme Is to Blame for Quick Fatigue
Howard Hughes Medical Institute scientists have uncovered a molecular explanation for the profound fatigue brought on by mild exercise in some people with muscular dystrophy.The drugs might be helpful because they would increase...
|
|
|
AVI BioPharma Strengthens P
PORTLAND, OR - AVI BioPharma Inc.(AVII), a developer of RNA-based drugs, announced in a Monday press release the signing of an exclusive worldwide license agreement with the University of Western Australia (UWA) to a patent application...
Intellectual Property News Agency:
Nov 26 2008 4:58PM
Matching: muscular dystrophy duchenne
|
Find similar documents
|
|
|
|
AVI BioPharma strengthens patent position in exon skipping
AVI BioPharma, Inc, a developer of RNA-based drugs, has signed an exclusive worldwide license agreement with the University of Western Australia (UWA) to a patent application related to the treatment of Duchenne Muscular ...
|
|
|
AVI BioPharma signs licensing agreement with University of Western Australia
(Datamonitor via COMTEX) -- AVII | Quote | Chart | News | PowerRating -- AVI BioPharma, a developer of RNA-based drugs, has signed an exclusive worldwide license agreement with the University of Western Australia to a patent application...
|
|
|
AVI BioPharma signs licensing agreement with University of Western Australia
The patent application claims compositions and methods for treating Duchenne muscular dystrophy (DMD) in humans by skipping exons in the dystrophin gene using antisense oligomers.Among the inventors on the licensed patent...
|
|
|
AVI BioPharma Strengthens Patent Position in Exon Skipping
AVI BioPharma, Inc.(NASDAQ: AVII), a developer of RNA-based drugs, today announced the signing of an exclusive worldwide license agreement with the University of Western Australia (UWA) to a patent application related to the treatment of ...
|
|
|
AVI BioPharma signs worldwide license agreement with UWA - Quick Facts
(RTTNews) - AVI BioPharma Inc.(AVII: News ) announced the signing of an exclusive worldwide license agreement with the University of Western Australia, or UWA to a patent application related to the treatment of Duchenne Muscular...
|
|
|
AVI BioPharma Strengthens Patent Position in Exon Skipping
-- AVI BioPharma, Inc.(NasdaqGM:AVII - News), a developer of RNA-based drugs, today announced the signing of an exclusive worldwide license agreement with the University of Western Australia (UWA) to a patent application related to the...
|
|
|
CombinatoRx, Incorporated (CRXX) Concentrates on Core Strengths, Cuts Staff by 30 Bringing Total Workforce Red
CAMBRIDGE, Mass.--(BUSINESS WIRE)--CombinatoRx, Incorporated (NASDAQ: CRXX) today announced a further restructuring, effective immediately, to focus on the core strength of the company: identifying novel product candidates based on...
|
|
|
Combination of Two Molecules Blocked at Root of Muscular Dystrophy
Using a drug discovery technique known as dynamic combinatorial chemistry, scientists at the University of Rochester Medical Center have identified several compounds that obstruct the unwanted coupling of two molecules that cause myotonic ...
|
|
|
Gene Therapy - Study findings from University of Missouri, Medical Department broaden understanding of gene th
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly We're a pay-per-view site for premium content.If you'd like to purchase this article, it's only $3.00. Gene Therapy Study findings from University of Missouri,...
|
|
|
The Gavriel Meir Trust Adds $450,000 to Extend Existing Collaboration between Charley's Fund/Nash Avery Founda
-Charleys Fund, Nash Avery Foundation and The Gavriel Meir Trust all non-profit organizations founded to support Duchenne muscular dystrophy (DMD) research, today announced an extension to the existing collaborative agreement...
|
|
|
CombinatoRx receives $450K for muscular dystrophy R&D
A local biopharmaceuticals company is set to receive a nearly half-million dollar infusion to find a cure to the most common form of muscular dystrophy.Cambridge-based CombinatoRx Inc. (Nasdaq: CRXX) on Wednesday said that the...
|
|
|
The Gavriel Meir Trust Adds $450,000 to Extend Existing Collaboration between Charley's Fund/Nash Avery Founda
- Charley's Fund, Nash Avery Foundation and The Gavriel Meir Trust all non-profit organizations founded to support Duchenne muscular dystrophy (DMD) research, today announced an extension to the existing collaborative agreement...
|
|
|
The Gavriel Meir Trust Adds $450,000 to Extend Existing Collaboration between Charley's Fund/Nash Avery Founda
- Charley 'We are pleased to extend and continue our work in the area of DMD, these research funds will further leverage our combination High Throughput Screening (cHTS The new collaboration will focus on the use of the CombinatoRx cHTS...
|
|
|
The Gavriel Meir Trust Adds $450,000 to Extend Existing Collaboration between Charley's Fund/Nash Avery Founda
'We are pleased to extend and continue our work in the area of DMD, these research funds will further leverage our combination High Throughput Screening (cHTS„ The new collaboration will focus on the use of the CombinatoRx cHTS&...
|
|
|
Santhera presents preclinical data on oral MC4 receptor antagonists for treatment of cancer cachexia at AICR r
LIESTAL, Switzerland - Santhera Pharmaceuticals announced preclinical data on a novel generation of melanocortin-4 (MC4) receptor antagonists for potential treatment of cancer cachexia (severe muscle wasting).The most advanced candidates...
|
|
|
Insmed Gains Royalty-Free Worldwide Rights for IPLEX in Connection with Potential Expanded Access ALS Programs
/PRNewswire-FirstCall/ -- Insmed Inc., a developer of follow-on biologics and biopharmaceuticals, today announced that Genentech, Ipsen/Tercica and Insmed jointly issued the following statement: Genentech, Ipsen/Tercica, and Insmed have...
|
|
|
Global Therapeutics Initiates Trial Of Next Generation Drug-Eluting Stent Using RNA Therapeutic Agent To Treat
BROOMFIELD, Colo.--(BUSINESS WIRE)--Global Therapeutics, a leading developer of innovative solutions for the cardiology market, today announced initiation of the world's first clinical trial of a drug eluting stent that uses an antisense RNA...
|
|
|
AVI BioPharma Announces Third Quarter 2008 Financial Results
AVI BioPharma, Inc.(NASDAQ: AVII), a developer of RNA-based drugs, today reported financial results for the three and nine months ending September 30, 2008. Revenues for the 2008 third quarter were $5.2 million, up from $2.9 million in...
|
|
|
AVI BioPharma Announces Third Quarter 2008 Financial Results
-- AVI BioPharma, Inc.(NasdaqGM:AVII - News), a developer of RNA-based drugs, today reported financial results for the three and nine months ending September 30, 2008. Revenues for the 2008 third quarter were $5.2 million, up from $2.9...
|
|
|
Insmed Gains Royalty-Free Worldwide Rights for IPLEX(TM) in Connection with Potential Expanded Access ALS Prog
Bitter Divorce Battle of Madonna Taking Toll on Her Mental Health!(7 hrs ago) Women With Serious Mental Illness may Give Birth to Stillborn Babies(7 hrs ago) Can Vitamin C & E Supplements Reduce the Risk of Cardiovascular Disease in...
|
|
|
OTCPicks.com: OTCPicks.com Daily Market Movers Digest Midday Report for Monday, November 10th UBRG, RNNM, CYCL
Our Stocks to Watch today include Universal Bioenergy Inc.(OTC: UBRG), Ronn Motor Company Inc. (OTC: RNNM), Centennial Communications Inc. (Nasdaq: CYCL), Certified Environmental Group Inc. (OTC: CENV), Puda Coal Inc. (OTCBB: PUDC...
|
|
|
Insmed Gains Royalty-Free Worldwide Rights for IPLEX(TM) in Connection with Potential Expanded Access ALS Prog
RICHMOND, Va., Nov.10 /PRNewswire-FirstCall/ -- Insmed Inc. (NASDAQ: INSM) , a developer of follow-on biologics and biopharmaceuticals, today announced that Genentech, Ipsen/Tercica and Insmed jointly issued the following statement:...
|
